Lenakast (Lenalidomide) 25 mg, 30 capsules: profile, composition and research
Reference page for Lenakast (Lenalidomide) 25 mg, 30 capsules. Active substance: Леналидомид / Lenalidomide.
- What it is: lenalidomide, an immunomodulatory antineoplastic substance.
- Presentation: 25 mg capsules, 30 capsules per pack.
- Status: prescription-only medicine used in oncology and haematology.
- Research: work in multiple myeloma and myelodysplastic syndromes, links below.
- Where to buy: APV Pharmacy (price and availability there).
Key facts
| Active substance | Lenalidomide |
|---|---|
| Form | Capsules |
| Strength | 25 mg per capsule |
| Pack size | 30 capsules |
| Category | Prescription medicine |
| Article (SKU) | LENK-25-30 |
What lenalidomide is
Lenalidomide is a substance that acts on tumour cells and on the immune system at the same time. It is chemically close to thalidomide, but its profile was deliberately reworked to reduce part of the unwanted effects and widen its use in haematology.
The substance is included in regimens for malignant blood diseases. It comes as capsules, which suits the long courses that can run for months under medical supervision.
Each pack contains 30 capsules of 25 mg. The strength and the pack size are listed above; the dose itself and the length of treatment are set individually.
How lenalidomide works
The intracellular target
The substance binds to cereblon, a protein that forms part of the cell's system for tagging unwanted proteins. As a result the set of proteins the cell destroys changes.
Tumour growth factors
Among the proteins broken down faster are transcription factors that keep tumour cells multiplying. The cell loses part of its signal to divide.
The immune response
Lenalidomide strengthens T lymphocytes and natural killer cells, that is the body's own immune cells directed against the tumour.
Tumour blood supply
A separate side of its action is the suppression of new vessel formation that feeds tumour tissue.
Approved uses
The prescribing information describes two main directions. The first is multiple myeloma, a tumour of the plasma cells of the bone marrow. The second is myelodysplastic syndromes, in which the formation of blood cells is disturbed.
Among the myelodysplastic syndromes, cases with a deletion of the long arm of chromosome 5 are singled out; in this group lenalidomide is used particularly often.
The medicine is given within combinations or as maintenance therapy rather than as a self-chosen option. The decision belongs to a haematologist or oncologist, based on examination results.
Lenalidomide affects blood formation, so blood counts are checked regularly during treatment and therapy is adjusted accordingly.
What to keep in mind
Lenalidomide can cause severe birth defects. It is therefore not used in pregnancy, and a confirmed negative test is required before treatment starts. Reliable contraception is needed for the duration of therapy.
Serious risks include a fall in blood cell counts, infections, venous thrombosis and thromboembolism. A physician may prescribe prevention of these complications.
Rash, fatigue, digestive symptoms and swelling are also possible. Any new symptom should be reported to a doctor.
The medicine may be dispensed only on lawful grounds and on a physician's prescription. Using such medicines on one's own is not acceptable.
Published research
Primary sources, verified against PubMed:
- Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis., PubMed 42637879 (Leukemia, 2026).
- Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma., PubMed 42456135 (N Engl J Med, 2026).
- A precision medicine approach to the myelodysplastic syndrome with isolated deletion 5q, 50 years after its discovery., PubMed 40758958 (Blood, 2025).
Listed for reference. Publication of a study is not a claim about this particular product.
Precautions
- This is a prescription medicine and is used only under the supervision of a haematologist or oncologist.
- Lenalidomide causes severe birth defects. It is contraindicated in pregnancy, and a confirmed negative pregnancy test is required before treatment starts.
- Reliable contraception is needed during treatment and for the period a doctor specifies afterwards. Breastfeeding is stopped.
- Treatment affects the blood: neutrophil, platelet and red-cell counts may fall, and infections may occur. Monitoring tests are ordered by a physician.
- The risk of thrombosis is raised, so a physician may recommend preventive measures.
- Liver or kidney impairment, as well as bone-marrow conditions, require separate assessment by a doctor.
- Tell your doctor about every other medicine you take: interactions are possible.
Frequently asked
Is Lenakast a prescription medicine?
Yes. It is a prescription antineoplastic medicine and must not be used on one's own.
Why does this page not give a dosing schedule?
In blood diseases the regimen is chosen individually and depends on the diagnosis, the patient's condition and test results. The dose and duration are set by a physician.
Can it be taken during pregnancy?
No. Lenalidomide is contraindicated in pregnancy and requires reliable contraception during treatment.
Where does the order ship from?
Shipping and customs handling are described on the APV Pharmacy delivery page.